Close Menu

NEW YORK (GenomeWeb) – Qiagen said after the close of the market on Wednesday that Laboratory Corporation of America has joined its "Day-One" lab readiness program designed to expedite patient access to Qiagen companion diagnostic products following regulatory approval of the tests and associated drugs.

Qiagen's Day-One program is intended to enable molecular diagnostic labs to begin preparing for commercial launch of new drugs and in vitro diagnostic tests being developed by Qiagen and its partners once US Food and Drug Administration approval is obtained.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.

Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.

Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.

In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.